Abstract:Corneal diseases represent 5.1% of all eye defects and are the fourth leading cause of blindness globally. Corneal neovascularization can arise from all conditions of chronic irritation or hypoxia, which disrupts the immune‐privileged state of the healthy cornea, increases the risk of rejection after keratoplasty, and leads to opacity. In the past decades, significant progress has been made for neovascular diseases of the retina and choroid, with plenty of drugs getting commercialized. In addition, to overcome the barriers of the short duration and inadequate penetration of conventional formulations of antivascular endothelial growth factor (VEGF), multiple novel drug delivery systems, including adeno‐associated virus (AAV)‐mediated transfer have gone through the full process of bench‐to‐bedside translation. Like retina neovascular diseases, corneal neovascularization also suffers from chronicity and a high risk of recurrence, necessitating sustained and efficient delivery across the epithelial barrier to reach deep layers of the corneal stroma. Among the explored methods, adeno‐associated virus‐mediated delivery of anti‐VEGF to treat corneal neovascularization is the most extensively researched and most promising strategy for clinical translation although currently although, it remains predominantly at the preclinical stage. This review comprehensively examines the necessity, benefits, and risks of applying AAV vectors for anti‐VEGF drug delivery in corneal vascularization, including its current progress and challenges in clinical translation.

A Review on Vasohibin and Ocular Neovascularization

Contribution of VEGF and PEDF to Choroidal Angiogenesis: A Need for Balanced Expressions

Progress of Anti-Vascular Endothelial Growth Factor Therapy for Ocular Neovascular Disease: Benefits and Challenges

Research Progress of VEGFR Small Molecule Inhibitors in Ocular Neovascular Diseases

Antiangiogenic Therapy for Ocular Diseases: Current Status and Challenges

Advances in vascular endothelial growth factor antagonist therapy for ocular neovascularization diseases

Vascular endothelial growth factor and intraocular neovascularization

Advancements in Neovascular Ophthalmopathy: Therapeutic Strategies and Future Prospects

Progression and Challenge of Anti-Vascular Endothelial Growth Factor Therapy in Retinal Neovascular Disease

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

[Intraocular Antiangiogenic Drugs in Clinical Application Advantages and Disadvantages].

Applications of nanomaterials in anti-VEGF treatment for ophthalmic diseases

Vascular endothelial growth factor in eye disease

Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno‐associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation

A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics

Targeting angiogenesis in oncology, ophthalmology and beyond

[Effects of Intravitreal Injection of Anti-vascular Endothelial Growth Factor Drugs on Ocular Blood Vessels and Blood Flow in Patients with Diabetic Retinopathy].

Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies

Up-to-date molecular medicine strategies for management of ocular surface neovascularization

Review of the Progress in Corneal Neovascularization Animal Models

Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications